AR and Familial prostate cancer: Leppänen et al. revealed that the AR inhibitor, enzalutamide (ENZ), increased the chromatin accessibility and expression of SIX2, facilitating stem-like reprogramming, neuroendocrine differentiation, and AR inhibitors resistance.554 ONECUT2 was a prostate cancer trigger through remodel the chromatin accessibility landscape independent of AR.